{
    "clinical_study": {
        "@rank": "30201", 
        "arm_group": {
            "arm_group_label": "RLY5016", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To assess the pharmacodynamic effects of RLY5016 on serum potassium in hemodialysis patients"
        }, 
        "brief_title": "An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of RLY5016 in Hemodialysis Patients", 
        "completion_date": {
            "#text": "December 2008", 
            "@type": "Actual"
        }, 
        "condition": "Hyperkalemia", 
        "condition_browse": {
            "mesh_term": "Hyperkalemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hemodialysis patients between the ages of 18 and 70 years, with serum potassium\n             levels of at least 5.5 mmol/L\n\n          -  Adequately dialyzed (Kt/V \u2265 1.2)\n\n        Exclusion Criteria:\n\n          -  History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders\n             or major gastrointestinal surgery.\n\n          -  Severe constipation or irregular bowel habits.\n\n          -  Unable to consume or tolerate the study-specific diet."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033317", 
            "org_study_id": "RLY5016-201"
        }, 
        "intervention": {
            "arm_group_label": "RLY5016", 
            "description": "15 grams/day (5 grams 3 times daily) administered orally", 
            "intervention_name": "RLY5016", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Facility"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "Research Facility"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of RLY5016 in Hemodialysis Patients", 
        "overall_official": {
            "affiliation": "Relypsa, Inc.", 
            "last_name": "Director Clinical Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in serum potassium", 
            "safety_issue": "No", 
            "time_frame": "8 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033317"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change from baseline in fecal potassium excretion", 
            "safety_issue": "No", 
            "time_frame": "8 Days"
        }, 
        "source": "Relypsa, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Relypsa, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2008", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}